Q&A: Kiran Mazumdar-Shaw, CMD, Biocon

'We focus on generating profit, not sales numbers'

has decided to divest its entire stake in Axicorp, its German subsidiary, by June. It also expects to post a more than 30 per cent operating margin in the current financial year. Kiran Mazumdar-Shaw, chairman & managing director, spoke to Debasis Mohapatara about plans and concerns. Edited excerpts:

What is the rationale behind divestment in your German subsidiary?
We bought majority stake in to market our products, namely insulin and glargine, in Germany. However, the relevance of this subsidiary has changed, as we entered into an out-licensing deal with in October last year to market these two products in the global market. Also, if you see the numbers, while Biocon’s operating margin is at 32 per cent, it is two per cent for Axicorp. So, this divestment will improve profitability of our business.

But contributes around 35 per cent (Rs 980 crore) towards Biocon’s top line. Will you be able to protect these numbers?
We focus on generating profit, not sales numbers. Also, the gap between revenue numbers is squeezing. For example, had a revenue of around Rs 2,370 crore in FY10, including Axicorp. This year, revenue from alone is around Rs 1,800 crore. So, the gap between total revenue and Biocon’s contribution to it is slowly narrowing. However, we may not able to compensate the total revenue figure from in the current financial year. Also, it may happen that we may post higher revenue numbers in the current fiscal due to our sound product pipeline.

Your outlook on margin and profitability?
We should be able to post more than 30 per cent margin in the current financial year. However, I will not be able to give any guidance on profitability and revenue numbers.

Milestone payment showed significant growth in 2010-11. How much will the company receive in the current financial year?
has received Rs 32 crore as licensing income during the last quarter of FY11, against Rs 20 crore last year. For the whole year, it was Rs 155 crore, a more than three-fold rise against last year. We should be able to sustain these numbers in the current financial year.

Any update on international partnership for your oral insulin programme?
Recent trials of oral insulin have met all safety requirements. We are looking for partnership for the oral insulin programme. There is huge interest in this space. We are likely to close a deal by the end of the current financial year.

What is your capital expenditure plan for the current year? Will you raise capital to fund growth?
We are planning to invest around Rs 200 crore in ramping up our manufacturing capacity and for research and development expenditure. This will come from internal accruals. Also, we will invest around $160 million (Rs 720 crore) for setting up manufacturing capacity in Malaysia over two-three years. As far as capital is concerned, we do have around Rs 500 crore as internal accruals. So, there is no need for raising capital at this point of time.

As both your contract research arms showed sound business growth, will you list these in the near future?
Our efforts of providing integrated contract research services have shown results and both Syngene and Clinigene have witnessed sound business growth. We definitely stick to our earlier plan of listing on the bourses, which will happen in the next 18-24 months.

image
Business Standard
177 22
Business Standard

Q&A: Kiran Mazumdar-Shaw, CMD, Biocon

'We focus on generating profit, not sales numbers'

Debasis Mohapatara 

Kiran Mazumdar-Shaw

has decided to divest its entire stake in Axicorp, its German subsidiary, by June. It also expects to post a more than 30 per cent operating margin in the current financial year. Kiran Mazumdar-Shaw, chairman & managing director, spoke to Debasis Mohapatara about plans and concerns. Edited excerpts:

What is the rationale behind divestment in your German subsidiary?
We bought majority stake in to market our products, namely insulin and glargine, in Germany. However, the relevance of this subsidiary has changed, as we entered into an out-licensing deal with in October last year to market these two products in the global market. Also, if you see the numbers, while Biocon’s operating margin is at 32 per cent, it is two per cent for Axicorp. So, this divestment will improve profitability of our business.

But contributes around 35 per cent (Rs 980 crore) towards Biocon’s top line. Will you be able to protect these numbers?
We focus on generating profit, not sales numbers. Also, the gap between revenue numbers is squeezing. For example, had a revenue of around Rs 2,370 crore in FY10, including Axicorp. This year, revenue from alone is around Rs 1,800 crore. So, the gap between total revenue and Biocon’s contribution to it is slowly narrowing. However, we may not able to compensate the total revenue figure from in the current financial year. Also, it may happen that we may post higher revenue numbers in the current fiscal due to our sound product pipeline.

Your outlook on margin and profitability?


We should be able to post more than 30 per cent margin in the current financial year. However, I will not be able to give any guidance on profitability and revenue numbers.

Milestone payment showed significant growth in 2010-11. How much will the company receive in the current financial year?
has received Rs 32 crore as licensing income during the last quarter of FY11, against Rs 20 crore last year. For the whole year, it was Rs 155 crore, a more than three-fold rise against last year. We should be able to sustain these numbers in the current financial year.

Any update on international partnership for your oral insulin programme?
Recent trials of oral insulin have met all safety requirements. We are looking for partnership for the oral insulin programme. There is huge interest in this space. We are likely to close a deal by the end of the current financial year.

What is your capital expenditure plan for the current year? Will you raise capital to fund growth?
We are planning to invest around Rs 200 crore in ramping up our manufacturing capacity and for research and development expenditure. This will come from internal accruals. Also, we will invest around $160 million (Rs 720 crore) for setting up manufacturing capacity in Malaysia over two-three years. As far as capital is concerned, we do have around Rs 500 crore as internal accruals. So, there is no need for raising capital at this point of time.

As both your contract research arms showed sound business growth, will you list these in the near future?
Our efforts of providing integrated contract research services have shown results and both Syngene and Clinigene have witnessed sound business growth. We definitely stick to our earlier plan of listing on the bourses, which will happen in the next 18-24 months.

RECOMMENDED FOR YOU

Q&A: Kiran Mazumdar-Shaw, CMD, Biocon

'We focus on generating profit, not sales numbers'

Biocon has decided to divest its entire stake in Axicorp, its German subsidiary, by June. It also expects to post a more than 30 per cent operating margin in the current financial year. Kiran Mazumdar-Shaw, chairman & managing director, spoke to Debasis Mohapatara about plans and concerns.

has decided to divest its entire stake in Axicorp, its German subsidiary, by June. It also expects to post a more than 30 per cent operating margin in the current financial year. Kiran Mazumdar-Shaw, chairman & managing director, spoke to Debasis Mohapatara about plans and concerns. Edited excerpts:

What is the rationale behind divestment in your German subsidiary?
We bought majority stake in to market our products, namely insulin and glargine, in Germany. However, the relevance of this subsidiary has changed, as we entered into an out-licensing deal with in October last year to market these two products in the global market. Also, if you see the numbers, while Biocon’s operating margin is at 32 per cent, it is two per cent for Axicorp. So, this divestment will improve profitability of our business.

But contributes around 35 per cent (Rs 980 crore) towards Biocon’s top line. Will you be able to protect these numbers?
We focus on generating profit, not sales numbers. Also, the gap between revenue numbers is squeezing. For example, had a revenue of around Rs 2,370 crore in FY10, including Axicorp. This year, revenue from alone is around Rs 1,800 crore. So, the gap between total revenue and Biocon’s contribution to it is slowly narrowing. However, we may not able to compensate the total revenue figure from in the current financial year. Also, it may happen that we may post higher revenue numbers in the current fiscal due to our sound product pipeline.

Your outlook on margin and profitability?
We should be able to post more than 30 per cent margin in the current financial year. However, I will not be able to give any guidance on profitability and revenue numbers.

Milestone payment showed significant growth in 2010-11. How much will the company receive in the current financial year?
has received Rs 32 crore as licensing income during the last quarter of FY11, against Rs 20 crore last year. For the whole year, it was Rs 155 crore, a more than three-fold rise against last year. We should be able to sustain these numbers in the current financial year.

Any update on international partnership for your oral insulin programme?
Recent trials of oral insulin have met all safety requirements. We are looking for partnership for the oral insulin programme. There is huge interest in this space. We are likely to close a deal by the end of the current financial year.

What is your capital expenditure plan for the current year? Will you raise capital to fund growth?
We are planning to invest around Rs 200 crore in ramping up our manufacturing capacity and for research and development expenditure. This will come from internal accruals. Also, we will invest around $160 million (Rs 720 crore) for setting up manufacturing capacity in Malaysia over two-three years. As far as capital is concerned, we do have around Rs 500 crore as internal accruals. So, there is no need for raising capital at this point of time.

As both your contract research arms showed sound business growth, will you list these in the near future?
Our efforts of providing integrated contract research services have shown results and both Syngene and Clinigene have witnessed sound business growth. We definitely stick to our earlier plan of listing on the bourses, which will happen in the next 18-24 months.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard